Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia

Neuropsychopharmacology

Volumn 38, Issue 10, 2013, Pages 1910-1920

  Rubio, María D ^a   Wood, Krista ^a   Haroutunian, Vahram ^b   Meador Woodruff, James H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

E1 activase; E3 ligase; Nedd8ylation; polyubiquitination; SUMOylation; Ufmylation

Indexed keywords

ALTEPLASE; GAMMA GLUTAMYL HYDROLASE; HALOPERIDOL DECANOATE; LIGASE; NEDD8 PROTEIN; PROTEASOME; UBIQUITIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; SCHIZOPHRENIA; SUMOYLATION; SUPERIOR TEMPORAL GYRUS; UBIQUITINATION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANIMALS; CASE-CONTROL STUDIES; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUMOYLATION; TEMPORAL LOBE; UBIQUITIN; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; UBIQUITINS;

EID: 84882454521     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.84     Document Type: Article

References (54)

1. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y et al (2005). Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 58: 85-96.
2. Aston C, Jiang L, Sokolov BP (2004). Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77: 858-866.
3. Barta PE, Pearlson GD, Powers RE, Richards SS, Tune LE (1990). Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry 147: 1457-1462.
4. Bauer D, Gupta D, Harotunian V, Meador-Woodruff JH, McCullumsmith RE (2008). Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr Res 104: 108-120.
5. Bousman CA, Chana G, Glatt SJ, Chandler SD, Lucero GR, Tatro E et al (2010a). Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples. Am J Med Genet B Neuropsychiatr Genet 153B: 494-502.
6. Bousman CA, Chana G, Glatt SJ, Chandler SD, May T, Lohr J et al (2010b). Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood. Am J Med Genet B Neuropsychiatr Genet 153B: 1336-1341.
7. Brandon NJ, Sawa A (2011). Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci 12: 707-722.
8. Chao HW, Hong CJ, Huang TN, Lin YL, Hsueh YP (2008). SUMOylation of the MAGUK protein CASK regulates dendritic spinogenesis. J Cell Biol 182: 141-155.
9. Choo YS, Vogler G, Wang D, Kalvakuri S, Iliuk A, Tao WA et al (2012). Regulation of parkin and PINK1 by neddylation. Hum Mol Genet 21: 2514-2523.
10. Deng C, Huang XF (2006). Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Exp Brain Res 168: 587-590.
11. Dil Kuazi A, Kito K, Abe Y, Shin RW, Kamitani T, Ueda N (2003). NEDD8 protein is involved in ubiquitinated inclusion bodies. J Pathol 199: 259-266.
12. Funk AJ, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2012). Abnormal activity of the MAPK- and cAMPassociated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology 37: 896-905.
13. Geiss-Friedlander R, Melchior F (2007). Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8: 947-956.
14. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR et al (2000). Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57: 1061-1069.
15. Haas KF, Broadie K (2008). Roles of ubiquitination at the synapse. Biochim Biophys Acta 1779: 495-506.
16. Hammond JC, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2011). Endosomal trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Schizophr Res 130: 260-265.
17. Hou Q, Gilbert J, Man HY (2011). Homeostatic regulation of AMPA receptor trafficking and degradation by light-controlled single-synaptic activation. Neuron 72: 806-818.
18. Hudson JJ, Chiang SC, Wells OS, Rookyard C, El-Khamisy SF (2012). SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair. Nat Commun 3: 733.
19. Kadare G, Toutant M, Formstecher E, Corvol JC, Carnaud M, Boutterin MC et al (2003). PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation. J Biol Chem 278: 47434-47440.
20. Kawakami T, Chiba T, Suzuki T, Iwai K, Yamanaka K, Minato N et al (2001). NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J 20: 4003-4012.
21. Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG et al (2012). Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol Cancer Res 10: 369-377.
22. Krumova P, Weishaupt JH (2012). Sumoylation in neurodegenerative diseases. Cell Mol Life Sci.
23. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R et al (2000). Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci USA 97: 9902-9906.
24. Larimore J, Tornieri K, Ryder PV, Gokhale A, Zlatic SA, Craige B et al (2011). The schizophrenia susceptibility factor dysbindin and its associated complex sort cargoes from cell bodies to the synapse. Mol Biol Cell 22: 4854-4867.
25. Lee PC, Sowa ME, Gygi SP, Harper JW (2011). Alternative ubiquitin activation/conjugation cascades interact with N-end rule ubiquitin ligases to control degradation of RGS proteins. Mol Cell 43: 392-405.
26. Lemaire K, Moura RF, Granvik M, Igoillo-Esteve M, Hohmeier HE, Hendrickx N et al (2011). Ubiquitin fold modifier 1 (UFM1) and its target UFBP1 protect pancreatic beta cells from ER stress-induced apoptosis. PLoS ONE 6: e18517.
27. Lin A, Hou Q, Jarzylo L, Amato S, Gilbert J, Shang F et al (2011). Nedd4-mediated AMPA receptor ubiquitination regulates receptor turnover and trafficking. J Neurochem 119: 27-39.
28. Loriol C, Khayachi A, Poupon G, Gwizdek C, Martin S (2012a). Activity-dependent regulation of the sumoylation machinery in rat hippocampal neurons. Biol Cell 105: 30-45.
29. Loriol C, Parisot J, Poupon G, Gwizdek C, Martin S (2012b). Developmental regulation and spatiotemporal redistribution of the sumoylation machinery in the rat central nervous system. PLoS ONE 7: e33757.
30. Mao Y, Sun M, Desai SD, Liu LF (2000). SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerasemediated DNA damage. Proc Natl Acad Sci USA 97: 4046-4051.
31. Melchior F (2000). SUMO-nonclassical ubiquitin. Annu Rev Cell Dev Biol 16: 591-626.
32. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P (2002). Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22: 2718-2729.
33. Mitsuda T, Omi T, Tanimukai H, Sakagami Y, Tagami S, Okochi M et al (2011). Sigma-1Rs are upregulated via PERK/eIF2alpha/ ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun 415: 519-525.
34. Moehle MS, Luduena RF, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE (2012). Regional differences in expression of beta-tubulin isoforms in schizophrenia. Schizophr Res 135: 181-186.
35. Mori F, Nishie M, Piao YS, Kito K, Kamitani T, Takahashi H et al (2005). Accumulation of NEDD8 in neuronal and glial inclusions of neurodegenerative disorders. Neuropathol Appl Neurobiol 31: 53-61.
36. Nenadic I, Smesny S, Schlosser RG, Sauer H, Gaser C (2010). Auditory hallucinations and brain structure in schizophrenia: voxel-based morphometric study. Br J Psychiatry 196: 412-413.
37. Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM (2011). Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 14: 285-293.
38. Plant LD, Dowdell EJ, Dementieva IS, Marks JD, Goldstein SA (2011). SUMO modification of cell surface Kv2.1 potassium channels regulates the activity of rat hippocampal neurons. J Gen Physiol 137: 441-454.
39. Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, Davis KL (1998). Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry 55: 205-211.
40. Rajarethinam RP, DeQuardo JR, Nalepa R, Tandon R (2000). Superior temporal gyrus in schizophrenia: a volumetric magnetic resonance imaging study. Schizophr Res 41: 303-312.
41. Rubio MD, Haroutunian V, Meador-Woodruff JH (2012). Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia. Biol Psychiatry 71: 906-914.
42. Scheuring D, Kunzl F, Viotti C, San Wan Yan M, Jiang L, Schellmann S et al (2012). Ubiquitin initiates sorting of Golgi and plasma membrane proteins into the vacuolar degradation pathway. BMC Plant Biol 12: 164.
43. Schubert KO, Focking M, Prehn JH, Cotter DR (2012). Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry 17: 669-681.
44. Sehat B, Andersson S, Girnita L, Larsson O (2008). Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 68: 5669-5677.
45. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R et al (2001). Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293: 263-269.
46. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S et al (1995). A functional neuroanatomy of hallucinations in schizophrenia. Nature 378: 176-179.
47. Sun J, Maller JJ, Guo L, Fitzgerald PB (2009). Superior temporal gyrus volume change in schizophrenia: a review on region of interest volumetric studies. Brain Res Rev 61: 14-32.
48. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ et al (2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113: 1353-1363.
49. van der Veen AG, Ploegh HL (2012). Ubiquitin-like proteins. Annu Rev Biochem 81: 323-357.
50. Varshavsky A (2012). The ubiquitin system, an immense realm. Annu Rev Biochem 81: 167-176.
51. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd, Donovan DM et al (2001). Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55: 641-650.
52. Weickert CS, Rothmond DA, Hyde TM, Kleinman JE, Straub RE (2008). Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizophr Res 98: 105-110.
53. Yin DM, Chen YJ, Sathyamurthy A, Xiong WC, Mei L (2012). Synaptic dysfunction in schizophrenia. Adv Exp Med Biol 970: 493-516.
54. Zheng W, Wang H, Zeng Z, Lin J, Little PJ, Srivastava LK et al (2012). The possible role of the Akt signaling pathway in schizophrenia. Brain Res 1470: 145-158..